Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK to develop and market Fabre-Kramer's antidepressants

Executive Summary

Continuing its recent streak of in-licensing near-term drug candidates, GlaxoSmithKline has gotten exclusive global rights to develop and sell Fabre-Kramer Pharmaceuticals' (specialty CNS pharma) Phase III gepirone ER plus follow-on molecules.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register